Psychedelics are playing an increasingly important role in psychiatric research, offering new hope for the treatment of psychiatric disorders. Esketamine, the enantiomer of ketamine, has been approved as a therapy for treatment-resistant depression (TRD) in multiple jurisdictions. ¹ In Australia, psilocybin for TRD and 3,4-methylenedioxymethamphetamine (MDMA) for post-traumatic stress disorder can be prescribed by authorised psychiatrists under strict regulatory controls. ² These approvals have reinforced their clinical optimism, but current evidence remains constrained by small samples, functional unblinding, expectancy effects, heterogeneous psychological support and limited long-term follow-up on safety and efficacy. ^{Reference Yao, Guo, Lu, Liu, Huang and Diao3} Unlike conventional pharmaceuticals, psychedelics exert effects through a complex interplay of pharmacology, psychotherapy and context. Therefore, whether the current evidence is sufficiently mature to warrant widespread clinical adoption must be critically assessed. ^{Reference Nutt, Crome and Young4} Addressing these challenges will require parallel progress in mechanistic study, clinical implementation, regulatory governance and public discourse (Fig. 1).

Fig. 1

From mechanism to clinical translation in psychedelic therapy. Psychedelics act through receptor or transporter systems, molecular signalling pathways, neuroplasticity and brain network dynamics, contributing to acute subjective effects or enduring therapeutic effects. Clinical translation requires parallel advances in four domains: mechanistic study to clarify whether acute subjective effects are necessary for therapeutic action; clinical implementation to demonstrate efficacy, define psychedelic-assisted therapy as a complex intervention and ensure safe delivery; regulatory governance to clarify responsibility, establish appropriate standards, strengthen patient safeguards and support fair access; and public discourse to avoid polarised views of psychedelics as either miracle cures or dangerous drugs. DMT, N,N-dimethyltryptamine; LSD, lysergic acid diethylamide; MDMA, 3,4-methylenedioxymethamphetamine; PAT psychedelic-assisted therapy. Fig. 1 was created with BioRender (web version accessed in 2026; macOS; Science Suite Inc., operating as BioRender, Toronto, Ontario, Canada; https://www.biorender.com/).

Fig. 1 Long description

Panel A: Mechanism. This panel shows the mechanisms of action for classic psychedelics like LSD, DMT, and psilocybin, as well as non-classic/atypical psychedelics like MDMA and ketamine. It includes receptor/transporter interactions, neuroplasticity, brain network dynamics, molecular signaling, acute subjective effects, and enduring therapeutic effects. Panel B: Clinical translation. This panel outlines the clinical translation of psychedelic therapy, focusing on psychiatric disorders such as post-traumatic stress disorder, anxiety disorders, obsessive-compulsive disorder, substance use disorders, and major depressive disorders. It also details mechanistic study, clinical implementation, regulatory governance, and public discourse, emphasizing the need for acute subjective effects, enduring therapeutic effects, efficacy demonstration, defining psychedelic-assisted therapy, safe delivery, responsibility, standards, patient safeguards, fair access, and avoiding polarized views of psychedelics.

A major theoretical challenge lies in understanding how, and whether, the acute subjective effects of psychedelics contribute to their enduring therapeutic effects. Preclinical studies link the acute subjective effects of psychedelics to 5-hydroxytryptamine 2A receptor activation and downstream Gq-phospholipase C signalling. ^{Reference Wallach, Cao, Calkins, Heim, Lanham and Bonniwell5} Enduring therapeutic effects are also commonly discussed in relation to brain-derived neurotrophic factor-tropomyosin receptor kinase B, mammalian target of rapamycin and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-receptor signalling, immediate-early gene responses, structural neuroplasticity and network-level changes. ^{Reference Kwan, Olson, Preller and Roth6} Notably, the relationship between acute subjective effects and enduring therapeutic effects remains ambiguous, and correlations with clinical outcomes do not establish mediation or causality. Are acute subjective effects, such as emotional breakthrough, enhanced meaning, mystical-type experiences or psychological insight, necessary mediators of therapeutic change, or merely by-products? If these experiences are essential, future studies must standardise the measurement of these subjective effects. Conversely, if they are not essential, future studies could explore whether compounds with minimal or no acute subjective effects offer one experimental route to dissociate plasticity-related mechanisms from altered states of consciousness. Such studies would help clarify whether therapeutic biological mechanisms can be retained while improving safety and clinical feasibility.

Furthermore, clinical implementation represents a major bottleneck in the clinical translation of psychedelics. This challenge can be considered across three key questions: how efficacy can be demonstrated, how psychedelic-assisted therapy (PAT) should be defined and how it can be safely delivered. First, assessing the specific therapeutic effects of psychedelics requires trial designs that separate drug-related benefits from expectancy effects, psychological support and treatment context. Unlike conventional drug trials, double-blind designs in psychedelic research are notoriously difficult to maintain because intense perceptual disturbances cause functional unblinding: participants can often infer whether they received the active drug or placebo. ^{Reference Lehrner, Hildebrandt and Yehuda7} Such design-related confounding compromises the interpretability of efficacy. Future trials must move beyond simple placebo controls and incorporate methods such as active placebos or low-dose comparators, expectancy assessment, pragmatic designs or formal evaluation of blinding integrity to mitigate these biases. Second, the monotherapy model is insufficient. PAT should be understood as a complex intervention requiring structured preparation, monitored dosing, integration sessions and an appropriate therapeutic setting. This complexity makes it difficult to disentangle the respective contributions of the drug, psychological support and treatment context. Third, safe delivery requires attention to patient selection, dosing strategy, therapist competence, crisis management and long-term follow-up. Dosing strategies should define a therapeutic window that accounts for individual variability, dosing intervals and related clinical factors. Subtherapeutic exposure may limit response whereas excessive dosing, particularly under suboptimal conditions or without adequate support, may induce dysphoria, disorganised thought and delusional perceptions. Because current trials are generally not designed to detect delayed or persistent adverse effects, psychedelic treatment should not be considered complete at the end of the dosing session. Clinical services should therefore include follow-up, systematic reporting of adverse events and clear pathways for managing affective instability, psychotic symptoms, functional deterioration and suicidality following PAT.

Developing appropriate regulatory governance for the clinical translation of psychedelics remains a pressing challenge. Regulators must oversee a new class of treatment that blurs the line between pharmacology and psychotherapy. Even where psychedelics have received regulatory approval for clinical use, approval should not be viewed as the finish line, but as the starting point for a regulated ecosystem. Such an ecosystem would need to clarify accountability across the treatment pathway, support equitable access to the full model of care and reduce the risk of diversion and misuse. If serious or unusual adverse reactions occur, responsibility may be difficult to assign. Harm may arise from either the compound itself or failures at different stages of the treatment pathway. Therefore, regulatory governance should clearly assign responsibilities across manufacturers, sponsors, clinical institutions, therapists and regulators. Translating these regulatory governance principles into practice requires standards for products and clinical services, safeguards for patients and reimbursement arrangements that support the full model of care. Product standards should address the manufacture, quality control, storage, dispensing and traceability of psychedelic compounds. Service standards should define therapist qualifications, treatment-setting requirements and emergency procedures. Patient safeguards should include appropriate eligibility and contraindication screening, informed consent, clinical monitoring, reporting of adverse events, crisis-management pathways and structured follow-up. PAT also entails substantial service costs because it requires trained therapists, preparation, dosing-day monitoring and integration. Thus, reimbursement should cover this full treatment pathway, not the compound alone. Together, these measures are needed to support safe and equitable access while reducing the risks of diversion and misuse.

Responsible public discourse on psychedelics requires moving beyond polarised narratives. Public narratives frequently swing between seeing psychedelics as a miracle cure and as a dangerous drug. Academic and media narratives should reject ‘psychedelic exceptionalism’ – the tendency to treat these substances with either undue reverence or excessive fear. Excessive enthusiasm can inflate expectations, complicate trial interpretation and encourage premature, unsupervised or poorly dosed use. Excessive fear, by contrast, can reinforce stigma and obstruct fair evaluation of legitimate therapeutic research. Communication must be balanced, transparently addressing both the therapeutic promise and current limitations, including uncertainties regarding long-term safety, persistent psychiatric or perceptual adverse effects and the potential for misuse.

Psychedelics have emerged as a promising therapeutic avenue for psychiatric disorders, yet their successful clinical translation necessitates concurrent advances across multiple domains. ^{Reference Jin, Ji, Liu, Lu, Hashimoto and Lu8} We propose that advances in mechanistic study, clinical implementation, regulatory governance and public discourse must proceed in parallel. The future of psychedelics in psychiatry should be judged not by enthusiasm or fear, but by whether the evidence, clinical boundaries and systems of care are strong enough to support safe and sustained use. Thus, psychedelics should be used in psychiatry only when there is reliable evidence of benefit, clear guidance for managing risks and sufficient service capacity to deliver treatment safely and equitably.